Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CGEM 
Cullinan Oncology LLC (CGEM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/28/2025: CGEM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $26.22
1 Year Target Price $26.22
| 8 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.74% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 476.14M USD | Price to earnings Ratio - | 1Y Target Price 26.22 |
Price to earnings Ratio - | 1Y Target Price 26.22 | ||
Volume (30-day avg) 9 | Beta -0.12 | 52 Weeks Range 5.68 - 17.50 | Updated Date 10/28/2025 |
52 Weeks Range 5.68 - 17.50 | Updated Date 10/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.42% | Return on Equity (TTM) -36.01% |
Valuation
Trailing PE - | Forward PE 6.3 | Enterprise Value 75714748 | Price to Sales(TTM) 26.88 |
Enterprise Value 75714748 | Price to Sales(TTM) 26.88 | ||
Enterprise Value to Revenue 11.55 | Enterprise Value to EBITDA -1.46 | Shares Outstanding 59074391 | Shares Floating 38232355 |
Shares Outstanding 59074391 | Shares Floating 38232355 | ||
Percent Insiders 0.86 | Percent Institutions 115.23 |
Upturn AI SWOT
Cullinan Oncology LLC
Company Overview
History and Background
Cullinan Oncology, Inc. is a biopharmaceutical company focused on developing a pipeline of targeted oncology therapies that are rooted in novel mechanisms. Founded in 2016, it went public in January 2021.
Core Business Areas
- Drug Development: Focuses on the discovery, development, and commercialization of oncology therapeutics.
Leadership and Structure
Owen Hughes is the Chief Executive Officer. The company has a board of directors and various management teams overseeing research and development, clinical operations, and corporate functions.
Top Products and Market Share
Key Offerings
- CLN-081 (EGFRi): An orally available, irreversible EGFR inhibitor selective for tumors harboring EGFRex20ins mutations. Market share is not readily available as it's in clinical development. Competitors include TAK-788 (mobocertinib, Takeda), amivantamab (JNJ), and poziotinib (Spectrum Pharmaceuticals). No revenue yet since in development.
- CLN-619 (MICA/MICB-targeted antibody): An antibody designed to activate NK cells and CD8+ T cells by targeting MICA/MICB proteins on cancer cells. Market share is not available due to its clinical stage of development. Competitors include other NK cell engagers and checkpoint inhibitors. No revenue yet since in development.
Market Dynamics
Industry Overview
The oncology therapeutics market is a large and rapidly growing market driven by an aging population, increasing cancer incidence, and advances in cancer treatment. The competitive landscape is crowded, with numerous pharmaceutical and biotechnology companies developing novel therapies.
Positioning
Cullinan Oncology is positioned as a developer of innovative, targeted oncology therapies. Its competitive advantage lies in its focus on novel mechanisms of action and its pipeline of early-stage clinical assets.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Cullinan Oncology is targeting specific subsets of cancer patients, positioning itself to capture a portion of this large TAM through targeted therapies.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approaches
- Experienced management team
- Strong financial position after IPO
- Diverse pipeline of clinical assets
Weaknesses
- Early stage clinical development - high risk
- Dependence on successful clinical trials
- Competition from larger pharmaceutical companies
- Limited commercial infrastructure
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through acquisitions or licensing
- Breakthrough Therapy Designation or other expedited regulatory pathways
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from existing and emerging therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- JNJ
- TAK
- SPPI
Competitive Landscape
Cullinan Oncology is a smaller player compared to established pharmaceutical companies. Its advantage lies in its focused pipeline and novel approaches, but it faces challenges in terms of resources and market access.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline expansion and progress through clinical trials.
Future Projections: Future growth depends on successful clinical trial outcomes and potential commercialization or partnerships.
Recent Initiatives: Advancing clinical trials for lead assets, exploring new targets and therapeutic modalities, and strengthening partnerships.
Summary
Cullinan Oncology is a clinical-stage biopharmaceutical company with a focus on developing targeted oncology therapies. Its strength lies in its innovative approach and pipeline of novel assets; however, it is subject to the risks inherent in drug development. Positive clinical trial results are essential for future success. They need to look out for clinical trial failures and regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Cullinan Oncology Investor Relations
- SEC Filings
- Third party market research reports.
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share estimates are based on available data and may not be precise. Investment decisions should be made based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Cullinan Oncology LLC
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 2021-01-08 | President, CEO & Director Mr. Nadim Ahmed | ||
Sector Healthcare | Industry Biotechnology | Full time employees 111 | Website https://cullinantherapeutics.com |
Full time employees 111 | Website https://cullinantherapeutics.com | ||
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.